Topical ranking of HPV testing in clinical practice;Aktuelle wertigkeit der HPV-testung in der klinischen praxis

Geburtshilfe und Frauenheilkunde

Volumn 62, Issue 6, 2002, Pages 543-549

  Tempfer, C ^a   Leodolter, S ^a   Kainz, C ^b  

^a UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; CANCER SCREENING; COLPOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; FEMALE; HEALTH PROGRAM; HUMAN; MORBIDITY; PATIENT CODING; PREVALENCE; REVIEW; RISK FACTOR; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CONIZATION; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; VIRUS IDENTIFICATION; VIRUS INFECTION; VIRUS TYPING; WART VIRUS;

EID: 0036306599     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-32419     Document Type: Review

References (41)

1. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: Baseline data from a randomized trial
2. Genital human papillomavirus infection in female university students as determined by a PCR-based method
3. Clearance of cervical human papillomavirus infection by treatment for cervical dysplasia
4. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors
5. Preventing cervical cancer
6. Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri
7. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: A preliminary study on 1518 women
8. HPV testing in primary screening of older women
9. A systematic review of the role of human papillomavirus testing within a cervical screening programme
10. Estimates of the cost impact of introducing human papilloma virus testing into a cervical screening programme
11. A population-based five-year follow-up study of cervical human papillomavirus infection
12. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer
13. Natural history of cervicovaginal papillomavirus infection in young women
14. Negative predictive value of human papillomavirus test following conization of the cervix uteri
15. Can papilloma virus testing be used to improve cervical cancer screening?
16. An analysis of factors that influence the ASCUS/SIL ratio of pathologists
17. Human papillomavirus testing as triage for atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions: Sensitivity, specificity, and cost-effectiveness
18. Regular disappearance of the human papillomavirus genome after conization of cervical dysplasia by carbon dioxide laser
19. HPV, histologic grade and age. Risk factors for the progression of cervical intraepithelial neoplasia
20. Value of human papillomavirus deoxyribonucleic acid testing after conization in the prediction of residual disease in the subsequent hysterectomy specimen
21. Identifying women with cervical neoplasia: Using human papillomavirus DNA testing for equivocal Papanicolaou results
22. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: Is it an alarm for disease recurrence?
23. The Bethesda System for reporting cervical/vaginal cytologic diagnoses
24. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia
25. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study
26. Human papillomavirus types and cervical squamous intraepithelial lesions that recur after cold-knife conization
27. Cervical neoplasia and other STD-related genital and anal neoplasias
28. Human papillomavirus testing and the outcome of treatment for cervical intraepithelial neoplasia
29. Determinants of genital human papillomavirus detection in a US population
30. Human papillomavirus testing for primary screening of cervical cancer precursors
31. High-risk types of human papillomavirus associated with the progression of cervical dysplasia to carcinoma
32. Prognostic features of cervical dysplasia associated with specific types of HPV DNA and cytologic features characteristic of HPV infection in dysplasia
33. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy
34. Evaluating cervical cancer screening programmes for developing countries
35. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: Baseline results from a randomized trial
36. High risk HPV persists after treatment of genital papillomavirus infection but not after treatment of cervical intraepithelial neoplasia
37. Present evidence on the value of HPV testing for cervical cancer screening: A model-based exploration of the (cost-)effectiveness
38. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
39. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer
40. Natural history of cervical human papillomavirus infection in young women: A longitudinal cohort study